Clinical Trial Finder | Pancreatic Cancer Action Network

Back to Trial Search

Phase Ib Study of Niraparib and TSR-042 in Patients with Unresectable or Metastatic Pancreatic Cancer, Breast, Ovary, Fallopian Tube, or Primary Peritoneal Cancer with a Known BRCA Mutation

Summary

The purpose of this phase Ib trial is to evaluate the safety and efficacy of niraparib and dostarlimab (TSR-042) in patients with unresectable or metastatic BRCA-mutated select cancers, including pancreatic cancer.

General Information

NCT#: NCT04673448
Study ID: RG1005140
Trial Phase: Phase I

Trial Sponsor: GlaxoSmithKline, University of Washington
Therapies Used in This Trial: Niraparib, Dostarlimab

Request a Healthcare Provider account to access Trial Eligibility and Site Information.

View Details

An authorized Healthcare Provider account is required to access Trial Eligibility and Site Information. Already have an account? Sign In

Request an Account

In order to view this information, you need to be signed in as a Health Care Provider.
You need to be signed in as a Health Care Provider. Please request an account.
In order to view this information, you need to be signed in as a Health Care Provider.
In order to see the trial eligibility criteria, you need to be signed in as a Health Care Provider.
This information is restricted to validated Health Care Providers.

Eligibility

-------------------------------------------------------------------------------------------

In order to view this information, you need to be signed in as a Health Care Provider.
You need to be signed in as a Health Care Provider. Please request an account by clicking on the Request button.
------------------------------------------------------------------------------------------------------
In order to view this information, you need to be signed in as a Health Care Provider. You are currently not authorized.

Site Information

Back to Trial Search